## Daniele Sblattero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9244750/publications.pdf

Version: 2024-02-01

116 papers 4,213 citations

36 h-index 128067 60 g-index

118 all docs

118 docs citations

118 times ranked

4092 citing authors

#	Article	IF	CITATIONS
1	A novel quantitative ELISA as accurate and reproducible tool to detect epidermal transglutaminase antibodies in patients with Dermatitis Herpetiformis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e78-e80.	1.3	7
2	Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis. Frontiers in Immunology, 2021, 12, 640070.	2.2	6
3	The Helicobacter pylori CagY Protein Drives Gastric Th1 and Th17 Inflammation and B Cell Proliferation in Gastric MALT Lymphoma. International Journal of Molecular Sciences, 2021, 22, 9459.	1.8	14
4	Management of coeliac disease patients after the confirmation of diagnosis in Central Europe. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, 27-32.	0.8	4
5	The Knowledge About Celiac Disease Among Healthcare Professionals and Patients in Central Europe. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 552-557.	0.9	15
6	Defining the Helicobacter pylori Disease-Specific Antigenic Repertoire. Frontiers in Microbiology, 2020, 11, 1551.	1.5	6
7	Proteomic Studies of the Biofilm Matrix including Outer Membrane Vesicles of Burkholderia multivorans C1576, a Strain of Clinical Importance for Cystic Fibrosis. Microorganisms, 2020, 8, 1826.	1.6	11
8	InteractomeSeq: a web server for the identification and profiling of domains and epitopes from phage display and next generation sequencing data. Nucleic Acids Research, 2020, 48, W200-W207.	6.5	7
9	Selection and characterization of highly specific recombinant antibodies against West Nile Virus E protein. Journal of Biotechnology, 2020, 311, 35-43.	1.9	6
10	High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. Oncolmmunology, 2019, 8, e1614856.	2.1	25
11	The RNAâ€binding protein ILF3 binds to transposable element sequences in SINEUP IncRNAs. FASEB Journal, 2019, 33, 13572-13589.	0.2	20
12	Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. Journal of Autoimmunity, 2019, 103, 102288.	3.0	33
13	A method for rapid and high-yield production of the tick-borne encephalitis virus E and DIII recombinant proteins in E. coli with preservation of the antigenic properties. Ticks and Tick-borne Diseases, 2019, 10, 935-941.	1.1	3
14	A Functional Idiotype/Anti-Idiotype Network Is Active in Genetically Gluten-Intolerant Individuals Negative for Both Celiac Disease–Related Intestinal Damage and Serum Autoantibodies. Journal of Immunology, 2019, 202, 1079-1087.	0.4	4
15	Phage Display Technology for Human Monoclonal Antibodies. Methods in Molecular Biology, 2019, 1904, 319-338.	0.4	10
16	Recombinant Antibody Selections by Combining Phage and Yeast Display. Methods in Molecular Biology, 2019, 1904, 339-352.	0.4	0
17	Mapping the minimum domain of the fibronectin binding site on transglutaminase 2 (TG2) and its importance in mediating signaling, adhesion, and migration in TG2â€expressing cells. FASEB Journal, 2019, 33, 2327-2342.	0.2	12
18	Interactome-Seq: A Protocol for Domainome Library Construction, Validation and Selection by Phage Display and Next Generation Sequencing. Journal of Visualized Experiments, 2018, , .	0.2	5

#	Article	IF	Citations
19	Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia. Cell Death and Disease, 2017, 8, e2592-e2592.	2.7	20
20	A label-free immunoassay for Flavivirus detection by the Reflective Phantom Interface technology. Biochemical and Biophysical Research Communications, 2017, 492, 558-564.	1.0	13
21	Transglutaminase 2-specific coeliac disease autoantibodies induce morphological changes and signs of inflammation in the small-bowel mucosa of mice. Amino Acids, 2017, 49, 529-540.	1.2	12
22	Celiac anti-type 2 transglutaminase antibodies induce differential effects in fibroblasts from celiac disease patients and from healthy subjects. Amino Acids, 2017, 49, 541-550.	1.2	8
23	Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Frontiers in Immunology, 2017, 8, 321.	2.2	30
24	Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. Frontiers in Immunology, 2017, 8, 1093.	2.2	20
25	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget, 2017, 8, 3274-3288.	0.8	13
26	OP0023â€Targeted Polymeric Nanoparticles as Diagnostic and Therapeutic Tool for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 61.2-61.	0.5	1
27	ICOS-Ligand Triggering Impairs Osteoclast Differentiation and Function In Vitro and In Vivo. Journal of Immunology, 2016, 197, 3905-3916.	0.4	34
28	FRIOO3Oâ€Anti-TNF-α Antibody Targeted To Inflamed Synovial Tissue for The Treatment of Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 436.2-437.	0.5	0
29	Rational Design of Antirheumatic Prodrugs Specific for Sites of Inflammation. Arthritis and Rheumatology, 2015, 67, 2661-2672.	2.9	18
30	Selecting soluble/foldable protein domains through single-gene or genomic ORF filtering: structure of the head domain of Burkholderia pseudomallei antigen BPSL2063. Acta Crystallographica Section D: Biological Crystallography, 2015, 71, 2227-2235.	2.5	15
31	SINEUPs are modular antisense long non-coding RNAs that increase synthesis of target proteins in cells. Frontiers in Cellular Neuroscience, 2015, 9, 174.	1.8	81
32	Engineering mammalian cell factories with SINEUP noncoding RNAs to improve translation of secreted proteins. Gene, 2015, 569, 287-293.	1.0	35
33	A8.18â€Tissue specific pro-drug for the next generation of anti-TNF therapy in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, A88.2-A89.	0.5	0
34	Recombinant renewable polyclonal antibodies. MAbs, 2015, 7, 32-41.	2.6	31
35	Identification of novel proteins binding the AU-rich element of $\hat{l}\pm$ -prothymosin mRNA through the selection of open reading frames (RIDome). RNA Biology, 2015, 12, 1289-1300.	1.5	5
36	SINEUPs: A new class of natural and synthetic antisense long non-coding RNAs that activate translation. RNA Biology, 2015, 12, 771-779.	1.5	84

#	Article	IF	Citations
37	Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. Leukemia, 2015, 29, 406-414.	3.3	64
38	Structural Basis for the Recognition in an Idiotype-Anti-Idiotype Antibody Complex Related to Celiac Disease. PLoS ONE, 2014, 9, e102839.	1.1	9
39	An Air-well sparging minifermenter system for high-throughput protein production. Microbial Cell Factories, 2014, 13, 132.	1.9	4
40	Development of an enzyme-linked immunosorbent assay for Bartonella henselae infection detection. Letters in Applied Microbiology, 2014, 59, 253-262.	1.0	4
41	B7h Triggering Inhibits the Migration of Tumor Cell Lines. Journal of Immunology, 2014, 192, 4921-4931.	0.4	40
42	Phage Display Technology for Human Monoclonal Antibodies. Methods in Molecular Biology, 2014, 1060, 277-295.	0.4	19
43	AB0122 In Vivo Intraarticular Binding of A Biopolymeric Compound in the Course of Experimental Immune Complex Induced Arthritis, Evaluated as A Potential Tool for Targeting Inflamed Synovium. Annals of the Rheumatic Diseases, 2014, 73, 844.2-844.	0.5	0
44	A nonâ $\in$ "complement-fixing antibody to $\hat{l}^2$ 2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood, 2014, 123, 3478-3487.	0.6	120
45	Anti-tissue transglutaminase antibodies activate intracellular tissue transglutaminase by modulating cytosolic Ca2+ homeostasis. Amino Acids, 2013, 44, 251-260.	1.2	21
46	Differential induction of IL-17, IL-10, and IL-9 in human T helper cells by B7h and B7.1. Cytokine, 2013, 64, 322-330.	1.4	22
47	A deep-blue OLED-based biochip for protein microarray fluorescence detection. Biosensors and Bioelectronics, 2013, 46, 44-47.	5.3	36
48	Profiling celiac disease antibody repertoire. Clinical Immunology, 2013, 148, 99-109.	1.4	27
49	Triggering of B7h by the ICOS Modulates Maturation and Migration of Monocyte-Derived Dendritic Cells. Journal of Immunology, 2013, 190, 1125-1134.	0.4	28
50	An Albumin-Derived Peptide Scaffold Capable of Binding and Catalysis. PLoS ONE, 2013, 8, e56469.	1.1	10
51	Celiac Anti-Type 2 Transglutaminase Antibodies Induce Phosphoproteome Modification in Intestinal Epithelial Caco-2 Cells. PLoS ONE, 2013, 8, e84403.	1.1	13
52	Celiac Disease–Specific TG2-Targeted Autoantibodies Inhibit Angiogenesis Ex Vivo and In Vivo in Mice by Interfering with Endothelial Cell Dynamics. PLoS ONE, 2013, 8, e65887.	1.1	22
53	Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5. PLoS ONE, 2013, 8, e58696.	1.1	24
54	A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 431-436.	3.3	62

#	Article	IF	CITATIONS
55	N-glycosylation of the mammalian dipeptidyl aminopeptidase-like protein 10 (DPP10) regulates trafficking and interaction with Kv4 channels. International Journal of Biochemistry and Cell Biology, 2012, 44, 876-885.	1.2	9
56	Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. Arthritis and Rheumatism, 2012, 64, 2559-2567.	6.7	39
57	RhoB is associated with the anti-angiogenic effects of celiac patient transglutaminase 2-targeted autoantibodies. Journal of Molecular Medicine, 2012, 90, 817-826.	1.7	11
58	Simple scale-up of recombinant antibody production using an UCOE containing vector. New Biotechnology, 2012, 29, 477-484.	2.4	37
59	Anti-cytokine autoantibodies in autoimmune diseases. American Journal of Clinical and Experimental Immunology, 2012, 1, 136-46.	0.2	25
60	Filtering "genic" open reading frames from genomic DNA samples for advanced annotation. BMC Genomics, 2011, 12, S5.	1.2	23
61	Cryptic genetic gluten intolerance revealed by intestinal antitransglutaminase antibodies and response to gluten-free diet. Gut, 2011, 60, 1487-1493.	6.1	43
62	Rapid interactome profiling by massive sequencing. Nucleic Acids Research, 2010, 38, e110-e110.	6.5	62
63	Impaired glycosylation blocks DPP10 cell surface expression and alters the electrophysiology of I to channel complex. Pflugers Archiv European Journal of Physiology, 2010, 460, 87-97.	1.3	17
64	Anti Transglutaminase Antibodies Cause Ataxia in Mice. PLoS ONE, 2010, 5, e9698.	1.1	93
65	B7h Triggering Inhibits Umbilical Vascular Endothelial Cell Adhesiveness to Tumor Cell Lines and Polymorphonuclear Cells. Journal of Immunology, 2010, 185, 3970-3979.	0.4	27
66	Inhibition of transglutaminase 2 enzymatic activity ameliorates the anti-angiogenic effects of coeliac disease autoantibodies. Scandinavian Journal of Gastroenterology, 2010, 45, 421-427.	0.6	16
67	Celiac anti-tissue transglutaminase antibodies interfere with the uptake of alpha gliadin peptide 31–43 but not of peptide 57–68 by epithelial cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 717-727.	1.8	32
68	Antibody library selection by the $\hat{l}^2$ -lactamase protein fragment complementation assay. Protein Engineering, Design and Selection, 2009, 22, 149-158.	1.0	16
69	Majority of Children With Type 1 Diabetes Produce and Deposit Anti-Tissue Transglutaminase Antibodies in the Small Intestine. Diabetes, 2009, 58, 1578-1584.	0.3	37
70	Mucosal tissue transglutaminase expression in celiac disease. Journal of Cellular and Molecular Medicine, 2009, 13, 334-340.	1.6	20
71	The transmembrane $\hat{I}^2$ -subunits KCNE1, KCNE2, and DPP6 modify pharmacological effects of the antiarrhythmic agent tedisamil on the transient outward current I to. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 617-626.	1.4	12
72	Selection and Characterization of a Novel Agonistic Human Recombinant Anti-Trail-R2 Minibody with Antileukemic Activity. International Journal of Immunopathology and Pharmacology, 2009, 22, 73-83.	1.0	9

#	Article	IF	CITATIONS
73	Profiling the Autoantibody Repertoire by Screening Phage-Displayed Human cDNA Libraries. Methods in Molecular Biology, 2009, 570, 353-369.	0.4	12
74	Primer sets for cloning the human repertoire of T cell Receptor Variable regions. BMC Immunology, 2008, 9, 50.	0.9	21
75	Anti-idiotypic response in mice expressing human autoantibodies. Molecular Immunology, 2008, 45, 1782-1791.	1.0	28
76	Using archaeal histones for precise DNA fragmentation. Protein Engineering, Design and Selection, 2007, 20, 267-271.	1.0	0
77	Plasmid incompatibility: more compatible than previously thought?. Protein Engineering, Design and Selection, 2007, 20, 309-313.	1.0	87
78	Humoral Immune Response to Tissue Transglutaminase Is Related to Epithelial Cell Proliferation in Celiac Disease. Gastroenterology, 2007, 132, 1245-1253.	0.6	78
79	Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models. BMC Biotechnology, 2007, 7, 46.	1.7	39
80	Gluten Ataxia: Passive Transfer in a Mouse Model. Annals of the New York Academy of Sciences, 2007, 1107, 319-328.	1.8	38
81	Cryptic gluten intolerance in type $1$ diabetes: identifying suitable candidates for a gluten free diet. Gut, 2006, 55, 133-134.	6.1	14
82	Looking for Celiac Disease: Diagnostic Accuracy of Two Rapid Commercial Assays. American Journal of Gastroenterology, 2006, 101, 1597-1600.	0.2	50
83	Thrombus formation induced by antibodies to $\hat{I}^2$ 2-glycoprotein I is complement dependent and requires a priming factor. Blood, 2005, 106, 2340-2346.	0.6	324
84	Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. European Journal of Immunology, 2005, 35, 2175-2183.	1.6	92
85	Characterization of the Anti-Tissue Transglutaminase Antibody Response in Nonobese Diabetic Mice. Journal of Immunology, 2005, 174, 5830-5836.	0.4	23
86	Characterizing monoclonal antibody epitopes by filtered gene fragment phage display. Biochemical Journal, 2005, 388, 889-894.	1.7	37
87	CREATION OF A MOUSE MODEL OF CELIAC DISEASE BY IN VIVO LONG TERM EXPRESSION OF DISEASE SPECIFIC ANTITRANSGLUTAMINASE ANTIBODY. Journal of Pediatric Gastroenterology and Nutrition, 2005, 40, 626.	0.9	1
88	Dual sugar gut-permeability testing on blood drop in animal models. Clinica Chimica Acta, 2005, 352, 191-197.	0.5	18
89	Antibodies in Proteomics., 2004, 248, 519-546.		4
90	Testing for Anti-Human Transglutaminase Antibodies in Saliva Is Not Useful for Diagnosis of Celiac Disease. Clinical Chemistry, 2004, 50, 216-219.	1.5	16

#	Article	IF	Citations
91	Mass screening for coeliac disease using antihuman transglutaminase antibody assay. Archives of Disease in Childhood, 2004, 89, 512-515.	1.0	185
92	Anti-Transglutaminase Antibodies and Age. Clinical Chemistry, 2004, 50, 1856-1860.	1.5	10
93	One-step cloning of anti tissue transglutaminase scFv from subjects with celiac disease. Journal of Autoimmunity, 2004, 22, 65-72.	3.0	16
94	Autoantibodies as predictors of disease. Lancet, The, 2004, 364, 1403-1404.	6.3	4
95	The Gut as Site of Production of Autoimmune Antibodies. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, S730-S731.	0.9	5
96	Antibodies in proteomics I: generating antibodies. Trends in Biotechnology, 2003, 21, 275-281.	4.9	50
97	Antibodies in proteomics II: screening, high-throughput characterization and downstream applications. Trends in Biotechnology, 2003, 21, 312-317.	4.9	57
98	Binders Based on Dimerised Immunoglobulin VH Domains. Journal of Molecular Biology, 2003, 333, 355-365.	2.0	13
99	Selecting Open Reading Frames From DNA. Genome Research, 2003, 13, 980-990.	2.4	49
100	Celiac disease in patients with sporadic and inherited cardiomyopathies and in their relatives. European Heart Journal, 2003, 24, 1455-1461.	1.0	41
101	Anti-tissue transglutaminase antibodies from coeliac patients inhibit transglutaminase activity both in vitro and in situ. Gut, 2002, 51, 177-181.	6.1	104
102	A Reliable Screening Procedure for Coeliac Disease in Clinical Practice. Scandinavian Journal of Gastroenterology, 2002, 37, 679-684.	0.6	44
103	The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. European Journal of Immunology, 2002, 32, 2773-2782.	1.6	40
104	The analysis of the fine specificity of celiac disease antibodies using tissue transglutaminase fragments. FEBS Journal, 2002, 269, 5175-5181.	0.2	55
105	In vivo recombination as a tool to generate molecular diversity in phage antibody libraries. Reviews in Molecular Biotechnology, 2001, 74, 303-315.	2.9	17
106	Antibodies in haystacks: how selection strategy influences the outcome of selection from molecular diversity libraries. Journal of Immunological Methods, 2001, 253, 233-242.	0.6	64
107	Molecular Dissection of the Tissue Transglutaminase Autoantibody Response in Celiac Disease. Journal of Immunology, 2001, 166, 4170-4176.	0.4	168
108	Exploiting recombination in single bacteria to make large phage antibody libraries. Nature Biotechnology, 2000, 18, 75-80.	9.4	321

#	Article	IF	CITATION
109	Analyzing the peripheral blood antibody repertoire of a celiac disease patient using phage antibody libraries. Human Antibodies, 2000, 9, 199-205.	0.6	11
110	Human Recombinant Tissue Transglutaminase Elisa: An Innovative Diagnostic Assay for Celiac Disease. American Journal of Gastroenterology, 2000, 95, 1253-1257.	0.2	174
111	Development of a novel rapid non-invasive screening test for coeliac disease. Gut, 2000, 47, 628-631.	6.1	76
112	Analyzing the peripheral blood antibody repertoire of a celiac disease patient using phage antibody libraries. Human Antibodies, 2000, 9, 199-205.	0.6	5
113	HUMAN TISSUE TRANSGLUTAMINASE ELISA: A POWERFUL MASS SCREENING DIAGNOSTIC ASSAY FOR COELIAC DISEASE. Journal of Pediatric Gastroenterology and Nutrition, 1999, 28, 568.	0.9	12
114	RAPID AND SIMPLE DOT IMMUNOBINDING ASSAY TO DETECT ANTI HUMAN-TRANSGLUTAMINASE ANTIBODIES IN COELIAC DISEASE. Journal of Pediatric Gastroenterology and Nutrition, 1999, 28, 563.	0.9	0
115	A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology: an International Journal of Immunological Engineering, 1998, 3, 271-278.	2.4	98
116	Extending filamentous phage host range by the grafting of a heterologous receptor binding domain. Gene, 1997, 185, 27-33.	1.0	51